X
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ATR-002
Therapeutic Area: Infections and Infectious Diseases Product Name: ATR-002
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 13, 2021
Details:
RESPIRE1 is an international, multi-center Phase II clinical trial in 220 adult patients with moderate to severe COVID-19, requiring hospitalization, but not requiring ICU admission or ventilator support at the time of screening or randomization.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): CVnCoV
Therapeutic Area: Infections and Infectious Diseases Product Name: CVnCoV
Highest Development Status: Phase II Product Type: Vaccine
Partner/Sponsor/Collaborator: Wacker Chemie AG
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement November 23, 2020
Details:
Under the terms of the initial agreement, WACKER will ramp up GMP (Good Manufacturing Practice) production of the mRNA drug substance for CVnCoV at its biotech site in Amsterdam in the first half of 2021.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): mRNA-based vaccines
Therapeutic Area: Infections and Infectious Diseases Product Name: CVnCoV
Highest Development Status: Phase II Product Type: Vaccine
Partner/Sponsor/Collaborator: European Commission
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement November 16, 2020
Details:
The mRNA vaccine will be supplied once it has proven to be safe and effective against COVID-19. CureVac will receive an upfront payment to support the advanced clinical development of CVnCoV, to ramp-up its manufacturing network, and market launch and supply preparations.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
